SphingoTec is pleased to announce the following appointments to its management team: Deborah Bergmann as Managing Director and Chief Executive Officer (CEO), Dr. Florian Uhle as Managing Director and…
With the mission of improving patient management in critical care settings, SphingoTec has started a series of collaboration with internationally leading academic and non-academic medical centers.
Bioactive Adrenomedullin (bio-ADM), is a dynamic biomarker for the real time assessment of endothelial function. Loss of endothelial function is causing the formation of edema, shock and subsequent…
PenKid Whitepaper
The whitepaper covers practical insights on the AKI diagnostics and highlights the scientific evidence for penKid, a kidney function biomarker.
Click here to download the…
SphingoTec has established an extended intellectual property portfolio covering markers for acute care conditions such as sepsis, acute heart failure and acute kidney injury.
Next to our Nexus IB10 automated and portable immunoassay system we also provide customized MTP assays and testing services to fulfill the specific requirements of our customers.
Our skilled international team has a breadth of experience in life sciences, disease biology, biotechnology, and clinical in vitro diagnostics and is dedicated to supporting the medical community and…
The sphingotest® Lightning is a reagent intended for quantitative in vitro diagnostics and used for automated chemiluminescence measurement of sphingotest® immunoluminometric assays (ILMA) using…